About this trial
Gallium-68-DOTATOC binds primarily with high affinity to somatostatin subtype 2 (SSTR2) receptors and these somatostatin receptors are also overexpressed on inflammation cells when activated.
The hypothesis is that the GATED mode on a Gallium-68-DOTATOC cardiac recording would be able to highlight abnormalities that could be correlated with the age of the patients and their cardiovascular risk factors.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old.
Having read and understood the information document.
Affiliated to a social security scheme.
Disqualifiers
Hypersensitivity during previous use of 68Ga-DOTATOC
Impossibility of performing a PET-CT (patient agitated, confused, etc.).
History of heart disease,
Severe arrhythmia that does not allow the PET synchronized with the ECG
Trial design
Single group
Treatments tested in this trial
Cardiac ECG-gated PET imaging will added
Other interventionBlood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
Treatment groups
Trial outcomes
Primary outcomes
Relationship between the captation of radiotracer and the cardiovascular disease
Measurement of myocardial activity
Secondary outcomes
Relationship between the captation of radiotracer and the troponin value
Correlation between the myocardial activity and the troponin value
Sponsors and contacts
Click on the lead sponsor to view all of their trials.